

MIMOTOPES OF HYPERVARIABLE REGION 1 OF THE
E2 GLYCOPROTEIN OF HCV AND USES THEREOF

The present invention is concerned with peptides, specifically
5 peptides which are mimotopes of the hypervariable region 1
(HVR1) of the putative envelope protein E2 of hepatitis C
virus (HCV). Employing a combination of techniques the
present inventors have devised a large number of peptides with
sequences based on consensus analysis of naturally occurring
10 HVR1 sequences and experimental determination of cross-
reactivity to antibodies against different isolates, none of
which peptides occurs in nature. The peptides are
individually useful in raising and obtaining antibodies, for
in vitro (e.g. diagnostic) and in vivo purposes, and libraries
15 of peptides are useful in identifying peptides of particular
cross-reactivity with antibodies able to bind a plurality of
HVR1's of different HCV strains. Peptides may be used in
themselves or as part of fusion proteins, for instance in
recombinant HCV E2 polypeptides, which may be incorporated
20 into recombinant HCV particles.

The HVR1 region of HCV is the most variable antigenic fragment
in the whole viral genome and is mainly responsible of the
large inter and intra-individual heterogeneity of the
25 infecting virus. It contains a principal neutralization

epitope and has been proposed as the major player in the mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, the development of an efficient prevention therapy is a very difficult task.

In devising the present invention, the inventors approached the problem of the HVR1 variability by deriving a consensus profile from more than two hundred HVR1 sequences from different viral isolates and used this consensus as a template for generating a vast repertoire of synthetic HVR1 surrogates. These were provided as fusions to the major coat protein VIII of M13 bacteriophage for display on the surface of bacteriophage particles. This library was affinity selected using many different sera from infected patients. Phage were identified which displayed high frequency of reactivity with patients' sera, but not with sera from uninfected controls. The selected sequences were shown to bind serum antibodies cross-reacting with a large panel of peptides reproducing the HVR1 from natural HCV variants.

In these "mimotopes" was identified a sequence pattern responsible for the observed cross-reactivity. When injected in experimental animals, the mimotopes with the highest cross-reactivity induced antibodies able to recognise the same panel

of natural HVR1 variants.

Hepatitis C virus (HCV) is the major etiologic agent of both blood-transfusion-associated and sporadic non-A non-B

5 hepatitis worldwide, with an estimated prevalence between 0.4 and 2% in the blood donor population (Choo et al., 1989). HCV infection leads to viral persistence and chronic disease in at least 70% of cases, among which a significant proportion eventually develops cirrhosis and hepatocellular carcinoma

10 (for a review see H. Alter, 1995). In spite of the availability of reliable serological tests for HCV diagnosis, community-acquired infection is still common and causes significant morbidity and mortality worldwide (Mast and Alter, 1993). In addition, interferon treatment, which is the only
15 anti-viral therapy available at the moment, is effective only in 20-30% of patients (Fried and Hoofnagle, 1995). Thus, development of an HCV vaccine represents a high priority project in the field.

20 The high frequency with which the virus establishes a persistent infection, despite a wide array of humoral and cell-mediated host immune responses, raised in the past some concerns about the existence of a protective immunity against HCV (Farci et al., 1992). As a matter of fact, protective
25 immunity against challenge with homologous virus could be

induced by vaccination of chimpanzees (the only other species susceptible to HCV infection) using recombinant forms of the putative envelope proteins E1 and E2 (Choo et al., 1994).

However, it remains to be established how effective this
5 response would be against heterologous viral inocula.

HCV exists in the bloodstream of infected patients as a quasispecies (Weiner et al., 1991; Martell et al., 1992; Martell et al., 1994; Kurosaki et al., 1994; Bukh et al.,
10 1995) which fluctuates during the course of the disease mainly as a result of immune pressure (Weiner et al., 1992; Kato et al., 1993; Kojima et al., 1994; Shimizu et al., 1994; van Doorn et al., 1995; Weiner et al., 1995). The emerging view is that chronic infection by HCV is not due to lack of humoral
15 or cellular responses, but rather to such responses being rendered ineffective by the high mutation rate of the virus which leads to the emergence of escape variants.

The existence of neutralising antibodies and their role in
20 protection from viral infection was documented by ex vivo neutralization of a pedigreed viral inoculum prior to injection into chimpanzees (Farci et al., 1994). This notwithstanding, neutralising antibodies were isolate-specific and seemed to be able to block only viral variants which were
25 present before the onset of the corresponding humoral response

(Farci et al., 1994). Even if the specificity of such neutralising antibodies is not well defined, both immunological and molecular evidence indicate that epitopes recognised by neutralising antibodies are localised in the hypervariable region 1 (HVR1) of the HCV genome (Farci et al., 1994). This consists of the N-terminal 27 amino acids of the E2 glycoprotein, the most variable region of the whole HCV polyprotein (Weiner et al., 1991). Direct proof for the role of anti-HVR1 antibodies in virus clearance came recently from ex vivo neutralization experiments. A rabbit anti-HVR1 hyperimmune serum raised against the predominant variant of an infectious HCV inoculum abolished its infectivity in one chimp, and partially protected a second animal by blocking propagation of the major variant present in the inoculum (Farci et al., 1996).

Thus, the evidence is that the HVR1 contains a principal neutralization determinant for HCV, and that it should constitute an essential component of an acellular HCV vaccine if one could surmount the problem of its variability. Relevant to this issue is the observation that anti-HVR1 antibodies from human sera display some degree of cross-reactivity to different HVR1 variants (Scarselli et al., 1995).

WO94/26306 (Chiron Corporation) discloses an attempt at identifying a consensus sequence within the HVR1 of HCV, based on sequence comparison on the 90 strains said to have been known as of 12 May 1993. The disclosed formula is of a

5 peptide including the following sequence: aa1-aa2-aa3-aa4-aa5-aa6, wherein aa1 is S, G, A, D, K, R or T; aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid; aa5 is any amino acid; and aa6 is G or A; with the proviso that the motif is not contained within a 31 amino acid sequence of a naturally occurring E2HV domain of an HCV isolate known as of May 12, 10 1993. In a further embodiment, aa7 is present and attached to aa6; aa7 being A, P or S. The 6 amino acid motif represents around 55,000 different sequence. The 7 amino acid motif represents around 165,000 different sequences.

15 Aspects of the present invention are based in part on a close inspection of the variability in HVR1 revealing that some positions of the HVR1 are less variable than others,

suggesting that the actual structural, and immunological

20 variability is more limited than that suggested by the heterogeneity in primary sequence. The invention is concerned in various aspects with providing "synthetic variants" of the HCV HVR1 which are immunologically similar to a plurality, preferably a great number of natural HVR1 variants and,

25 therefore, may be used to induce neutralising antibodies which

cross-react with different HCV variants, preferably most or all. As explained further below, the formulae arrived at for peptides of the present invention differs from that provided in WO94/26306, and is based on actual cross-reactivity scoring
5 rather than just sequence comparison.

Phage displayed peptide libraries offer the unique chance to rapidly survey large collections of peptidic sequences (10^8 or more) through a cyclic selection/rescue/amplification
10 procedure. They allow identification of ligands for any type of ligate ranging from linear peptides to folded protein domains, and even carbohydrates (Cortese et al., 1994, Cortese et al., 1996). These ligands are true mimotopes as they do not necessarily share the same amino acid sequence of the
15 original epitope, but they mimic its binding properties. A strategy for the identification of disease-specific phage-displayed mimotopes was reported previously, which avails itself only of clinically characterized sera from immune and non immune individuals (Folgori et al., 1994, hereby
20 incorporated by reference). Furthermore, disease-specific mimotopes proved to be good immunogenic mimics of the natural antigen as they were able to induce a specific immune response to the natural antigen when injected into different animals (Folgori et al., 1994, and Meola et al., 1995, (both hereby
25 incorporated by reference) Prezzi et al., 1996, Mecchia et

al., 1996). Thus, phage libraries may be used as a source of artificial ligands recognised by disease-specific antibodies, with the advantage that additional desirable features can be built-in, providing that they can be selected for during library enrichment.

In making the present invention, the inventors approached the problem of the HVR1 variability by generating a vast repertoire of HVR1 surrogates as fusion to the major coat protein (pVIII) of bacteriophage M13. Using the power of selection and many sera from clinically characterized HCV infected individuals peptides were isolated which revealed to be good antigenic and immunogenic mimics of a large number of naturally occurring HCV variants.

Experimental details are provided below.

In accordance with various aspects of the present invention there are provided libraries of peptides containing large numbers of different peptides, individual peptides which contain epitopes cross-reactive with a plurality of HCV HVR1 epitopes, and mixtures of different such peptides.

One aspect of the present invention provides a library of peptide conforming with the following consensus profile:

Q T H V T G G S A A R T T S G L T S L F S P G A S Q N
 T T T V V Q G H A A H S V G R L P K K
 R Q V S Q V R R R S S Q
 Q

- 5 This profile represents a total of 9×10^7 individual sequences, i.e. a number very close to the upper practical limit (about 10^8) of current DNA cloning and transformation techniques. As described below, this consensus profile was used for the construction of a 27aa peptide library by cloning
- 10 a degenerated synthetic oligonucleotide as a fusion to the 5' end of the gene coding for the major coat protein (pVIII) in a phagemid vector for M13. The library was extensively screened using human sera, and more than one hundred different clones (mimotopes) were selected for their characteristic to
- 15 specifically recognise human anti HCV-HVR1 antibodies. Nearly all these mimotopes have different amino acid sequences and none of them could be found to correspond to published (up to January 98) natural HVR1.
- 20 In a preferred embodiment of a peptide library according to the present invention there are at least about 10^5 different peptides present, preferably at least about 10^6 different peptides, more preferably at least about 10^7 , e.g. about 9×10^7 different peptides.

A library of peptides may be displayed on the surface of bacteriophage, particularly filamentous bacteriophage such as fd or M13, for instance as fusions with the major coat protein (pVIII) of such bacteriophage. Phage display of peptides is standard in the art and its power lies in the fact that bacteriophage particles are constructed so that packaged within each particle is nucleic acid encoding the peptide displayed on its surface. Following selection of phage particles displaying a peptide of interest, such as a peptide able to bind one or more antibodies (e.g. antibodies able to bind a number of epitopes of HVR1 of different strains of HCV), the nucleic acid encoding the displayed peptide can be retrieved and used in production of further peptide with that amino acid sequence.

In the experimental work described below, the inventors tested mimotopes in a library according to the present invention with a panel of human sera, and individual mimotopes were characterised as having a different overall frequency of reactivity with the sera. The 24 clones that only reacted with less than 3 sera were defined as "weak" while the 27 reacting with more than 11 sera were defined as "strong".

Statistical analysis of the consensus sequences of "strong" and "weak" clones, lead to the discovery of a sequence motif

in the HVR1 that is correlated with high frequency of reaction with human sera, crossreactivity with human anti HVR1 antibodies and induction of highly crossreactive sera in experimental animals.

5

Peptides according to the present invention, and mixtures thereof, may be defined as follows, further explanation of which is given below in the experimental section:

10 (1) - A library of peptides fully described by the following formula ("Formula I"):

Q T H V T G G S A A R T T S G L T S L F S P G A S Q N
 T T T V V Q G H A A H S V G R L P K K
 15 R Q V S Q V R R R S S Q
 Q

which may be written as

(aa1)T(aa3)(aa4)(aa5)GG(aa8)(aa9)(aa10)(aa11)(aa12)(aa13)(aa14
 20)(aa15)L(aa17)(aa18)LF(aa21)(aa22)G(aa24)(aa25)Q(aa27)

wherein aa1 is Q or T; aa3 is H, T or R; aa4 is V or T; aa5 is T or V; aa8 is S, V or Q; aa9 is A, Q or V; aa10 is A, G or S; aa11 is R or H; aa12 is T, A or Q; aa13 is T, A or V; aa14 is S, H or R; aa15 is G, S or R; aa17 is T or V; aa18 is S, G or
 25 R; aa21 is S or R; aa22 is P, L, S or Q; aa24 is A, P or S;

aa25 is S, K or Q; aa27 is N or K.

(2) - 27 "strong" peptides obtainable from such a library are preferred peptides according to various aspects of the present invention, having an amino acid sequence as follows:

2.11 QT H TVGGVQG R QAHSLT S LF S P G A SQN
D6 QT T TTGGQVS H ATHGLT G LF S L G P QQK
D18 QT H TTGGSAS H QASGLT R LF S Q G P SQN
10 F63 QT H VVGGQQG R QVSSLV S LF S P G A SQK
G31 TT H TVGGSVA R QVHSLT G LF S P G P QQK
L13 QT H TVGGSQA H AAHSLT R LF S P G S SQN
M69 QT T VVGSQA R AAHGLV S LF S L G S KQN
Z61 QT H VVGGVQG R QTSGLV G LF S P G S KQN
15 R9 QT T VVGSQS H TVRGLT S LF S P G A SQN
B26 TT T TTGGQAG H QAHSLT S LF S P G A SQK
B22 QT H VVGGVQS H QTSGLT S LF S P G A SQK
B35 QT H TTGGVQG H QTSRLT S LF S P G P SQN
D29 TT T VVGGQAA H QTHSLT S LF S P G A KQN
20 D33 TT T TTGGQQS H TVHGLV G LF S P G S KQN
E26 QT H TVGGVQA H TVRGLT S LF S P G S SQN
F80 QT H TTGGQAG H TASSLT G LF S P G A KQN
F19 QT T TVGGVAS H QAHSLT G LF S P G A KQK
F78 QT H TTGGQAG H QAHSLT G LF S P G A KQN
25 H1 QT H TTGGVVG H ATSGLT S LF S P G P SQK

L76 TT T TVGGQAS H QTSSLT G LF S P G S KQN
M27 QT T TTGGVAS H AAHRLT S LF S P G P QQK
M122 QT T TTGGSAS H AVSSLT G LF S P G S KQN
M129 QT T VVGGSAG H TASSLV G LF S P G S KQN
5 M119 TT T TVGGQAS H TTSSLT G LF S P G S QQN
R5 QT H TTGGQAS H QVSSLV S LF S P G A KQK
R6 TT T TTGGQVG H QTSGLT G LF S P G A QQN
R27 TT H VVGGSAS H AVRGLT S LF S P G S SQN

10

Further preferred peptides according to the present invention have any of the following sequences:

B14 QT T VTG_QAS H TTSSLT G LF S P G A SQK
15 B33 aT H aTGGQAA H STHSLT S LF S P G A SQK
F81 QT H VTGGSAA H QTgGLT G LF S P G P KQN
B18 QT T VVGQAS H _VSRLT G LF S P G S SQK
L72 QT T T____AA H TTSGLT G LF S P G A KQN
D20 QT H VTG_VAG R QTSGLV S LF S P G S SQN
20 D30 Q_ _ __GGVQG H TTSSLV G LF S P G S QQN
E19 TT H T_GGQQA H TTSRLV S LF S P G A SQK
B24 TT T TVGGQAS H TTSSLT G LF S P G A SQK
M63 QT H TTGGVVS H QTRSLV G LF S P G P QQN

25 The lower case letters are used to identify amino acid

residues that vary from Formula 1, while the underlined spaces are included to signify deletions compared with Formula 1, though the flanking amino acids are of course contiguous in the relevant peptides.

5

These are variants of peptides obtainable from a library in accordance with the present invention, not themselves conforming with Formula I. They were identified in the course of the experiments identified below and originated by PCR errors during library amplification. (See Materials and Methods, "Construction of the HVR1 library".)

10

(3) - A "strong consensus" ("Formula II"), derived from the consensus of the highly cross-reactive peptides of (2) above.

15

The statistical analysis of the frequencies of aa in any position in the 27 "strong" in comparison with the frequency in 25 "weak" is shown in Table II, and discussed further below in the experimental section.

20

Formula II:

25 QT(aa3)TVGGQQS(aa11)QVHSLT(aa18)LF(aa21)(aa22)G(aa24)SQN

where: aa3 is H or T; aa11 is H or R; aa18 is G, S or R; aa21 is S; aa22 is P, L or Q; aa24 is A, S or P;

which may also be written:

5

QT H TVGGQAS H QASSLT S LF S P G A KQN

T	R	G	L	S
		R	Q	P

Residues in italics are included because although they have low frequencies they are found in some of the best reactive mimotopes tested (highlighted with an asterisk among the 27 "strong" peptides at II above.

The 27 mimotopes used to derive Formula II are not in it.

15

108 peptides conform to Formula II and each is an aspect of the invention. The sequences are:

- 1 QHTV GQAS HQASS LTSLF SPQAK QN
- 2 QHTV GQAS HQASS LTSLF SPQSK QN
- 3 QHTV GQAS HQASS LTSLF SPQPK QN
- 4 QHTV GQAS HQASS LTSLF SLQAK QN
- 5 QHTV GQAS HQASS LTSLF SLQSK QN
- 6 QHTV GQAS HQASS LTSLF SLQPK QN
- 7 QHTV GQAS HQASS LTSLF SQQAK QN

8 QTHTV GGQAS HQASS LTSLF SQGSK QN
9 QTHTV GGQAS HQASS LTSLF SQGPK QN
10 QTHTV GGQAS HQASS LTGLF SPGAK QN
11 QTHTV GGQAS HQASS LTGLF SPGSK QN
5 12 QTHTV GGQAS HQASS LTGLF SPGPK QN
13 QTHTV GGQAS HQASS LTGLF SLGAK QN
14 QTHTV GGQAS HQASS LTGLF SLGSK QN
15 QTHTV GGQAS HQASS LTGLF SLGPK QN
16 QTHTV GGQAS HQASS LTGLF SQGAK QN
10 17 QTHTV GGQAS HQASS LTGLF SQGSK QN
18 QTHTV GGQAS HQASS LTGLF SQGPK QN
19 QTHTV GGQAS HQASS LTRLF SPGAK QN
20 QTHTV GGQAS HQASS LTRLF SPGSK QN
21 QTHTV GGQAS HQASS LTRLF SPGPK QN
15 22 QTHTV GGQAS HQASS LTRLF SLGAK QN
23 QTHTV GGQAS HQASS LTRLF SLGSK QN
24 QTHTV GGQAS HQASS LTRLF SLGPK QN
25 QTHTV GGQAS HQASS LTRLF SQGAK QN
26 QTHTV GGQAS HQASS LTRLF SQGSK QN
20 27 QTHTV GGQAS HQASS LTRLF SQGPK QN
28 QTHTV GGQAS RQASS LTSLF SPGAK QN
29 QTHTV GGQAS RQASS LTSLF SPGSK QN
30 QTHTV GGQAS RQASS LTSLF SPGPK QN
31 QTHTV GGQAS RQASS LTSLF SLGAK QN
25 32 QTHTV GGQAS RQASS LTSLF SLGSK QN

33 QTHTV GGQAS RQASS LTSLF SLGPK QN
34 QTHTV GGQAS RQASS LTSLF SQGAK QN
35 QTHTV GGQAS RQASS LTSLF SQGSK QN
36 QTHTV GGQAS RQASS LTSLF SQGPK QN
5 37 QTHTV GGQAS RQASS LTGLF SPGAK QN
38 QTHTV GGQAS RQASS LTGLF SPGSK QN
39 QTHTV GGQAS RQASS LTGLF SPGPK QN
40 QTHTV GGQAS RQASS LTGLF SLGAK QN
41 QTHTV GGQAS RQASS LTGLF SLGSK QN
10 42 QTHTV GGQAS RQASS LTGLF SLGPK QN
43 QTHTV GGQAS RQASS LTGLF SQGAK QN
44 QTHTV GGQAS RQASS LTGLF SQGSK QN
45 QTHTV GGQAS RQASS LTGLF SQGPK QN
46 QTHTV GGQAS RQASS LTRLF SPGAK QN
15 47 QTHTV GGQAS RQASS LTRLF SPGSK QN
48 QTHTV GGQAS RQASS LTRLF SPGPK QN
49 QTHTV GGQAS RQASS LTRLF SLGAK QN
50 QTHTV GGQAS RQASS LTRLF SLGSK QN
51 QTHTV GGQAS RQASS LTRLF SLGPK QN
20 52 QTHTV GGQAS RQASS LTRLF SQGAK QN
53 QTHTV GGQAS RQASS LTRLF SQGSK QN
54 QTHTV GGQAS RQASS LTRLF SQGPK QN
55 QTTTV GGQAS HQASS LTSLF SPGAK QN
56 QTTTV GGQAS HQASS LTSLF SPGSK QN
25 57 QTTTV GGQAS HQASS LTSLF SPGPK QN

58 QTTTV GGQAS HQASS LTSLF SLGAK QN
59 QTTTV GGQAS HQASS LTSLF SLGSK QN
60 QTTTV GGQAS HQASS LTSLF SLGPK QN
61 QTTTV GGQAS HQASS LTSLF SQGAK QN
5 62 QTTTV GGQAS HQASS LTSLF SQGSK QN
63 QTTTV GGQAS HQASS LTSLF SQGPK QN
64 QTTTV GGQAS HQASS LTGLF SPGAK QN
65 QTTTV GGQAS HQASS LTGLF SPGSK QN
66 QTTTV GGQAS HQASS LTGLF SPGPK QN
10 67 QTTTV GGQAS HQASS LTGLF SLGAK QN
68 QTTTV GGQAS HQASS LTGLF SLGSK QN
69 QTTTV GGQAS HQASS LTGLF SLGPK QN
70 QTTTV GGQAS HQASS LTGLF SQGAK QN
71 QTTTV GGQAS HQASS LTGLF SQGSK QN
15 72 QTTTV GGQAS HQASS LTGLF SQGPK QN
73 QTTTV GGQAS HQASS LTRLF SPGAK QN
74 QTTTV GGQAS HQASS LTRLF SPGSK QN
75 QTTTV GGQAS HQASS LTRLF SPGPK QN
76 QTTTV GGQAS HQASS LTRLF SLGAK QN
20 77 QTTTV GGQAS HQASS LTRLF SLGSK QN
78 QTTTV GGQAS HQASS LTRLF SLGPK QN
79 QTTTV GGQAS HQASS LTRLF SQGAK QN
80 QTTTV GGQAS HQASS LTRLF SQGSK QN
81 QTTTV GGQAS HQASS LTRLF SQGPK QN
25 82 QTTTV GGQAS RQASS LTSLF SPGAK QN

83 QTTTV GGQAS RQASS LTSLF SPGSK QN
84 QTTTV GGQAS RQASS LTSLF SPGPK QN
85 QTTTV GGQAS RQASS LTSLF SLGAK QN
86 QTTTV GGQAS RQASS LTSLF SLGSK QN
5 87 QTTTV GGQAS RQASS LTSLF SLGPK QN
88 QTTTV GGQAS RQASS LTSLF SQGAK QN
89 QTTTV GGQAS RQASS LTSLF SQGSK QN
90 QTTTV GGQAS RQASS LTSLF SQGPK QN
91 QTTTV GGQAS RQASS LTGLF SPGAK QN
10 92 QTTTV GGQAS RQASS LTGLF SPGSK QN
93 QTTTV GGQAS RQASS LTGLF SPGPK QN
94 QTTTV GGQAS RQASS LTGLF SLGAK QN
95 QTTTV GGQAS RQASS LTGLF SLGSK QN
96 QTTTV GGQAS RQASS LTGLF SLGPK QN
15 97 QTTTV GGQAS RQASS LTGLF SQGAK QN
98 QTTTV GGQAS RQASS LTGLF SQGSK QN
99 QTTTV GGQAS RQASS LTGLF SQGPK QN
100 QTTTV GGQAS RQASS LTRLF SPGAK QN
101 QTTTV GGQAS RQASS LTRLF SPGSK QN
20 102 QTTTV GGQAS RQASS LTRLF SPGPK QN
103 QTTTV GGQAS RQASS LTRLF SLGAK QN
104 QTTTV GGQAS RQASS LTRLF SLGSK QN
105 QTTTV GGQAS RQASS LTRLF SLGPK QN
106 QTTTV GGQAS RQASS LTRLF SQGAK QN
25 107 QTTTV GGQAS RQASS LTRLF SQGSK QN

108 QTTTV GQAS RQASS LTRLF SQGPK QN

(4) - A further library of peptides within the library of Formula I, including the sequences of Formula II, defining 2.5×10^6 sequences and conforming to the following Formula III:

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
 T T V T S Q G A T H G V G S S K
 V V A T V R R P Q

10

A peptide according to the present invention may be provided in a fusion with additional amino acids. Additional amino acids may be fused at one or both of the N-terminus and the C-terminus of the peptide. The additional amino acids may be an amino acid sequence that is not a fragment of HCV E2 protein, or may be an amino acid sequence that is part of that protein. Furthermore, a fusion including a peptide according to the present invention may include a HCV E2/NS1 protein with the peptide amino acid sequence in the HVR1 position, i.e. such that the mimotope HVR1 peptide of the invention substitutes for the natural HVR1 sequence. Another way of expressing this is to refer to a "recombinant HCV E2/NS1 protein in which a peptide of the present invention is substituted for the HVR1". As noted below, nucleic acid encoding peptides and polypeptides, including fusions, according to invention are

15
20
25

provided as further aspects of the invention, as is a recombinant HCV genome including a nucleotide sequence encoding a peptide of the invention, for instance within the E2/NS1 coding sequence to provide for production of a recombinant HCV E2/NS1 protein in which a peptide of the invention is substituted for the HVR1 and incorporation of the recombinant protein into an assembled HCV particle. A recombinant HCV particle including one or more peptides or polypeptides as disclosed herein is provided as a further aspect of the present invention.

Generally, a peptide according to the present invention is immunogenic or able to raise an immune response on administration to an individual or includes an epitope immunologically cross-reactive with an epitope of a plurality of strains of HCV.

Another aspect of the present invention provides a method of obtaining one or more peptides containing an epitope immunologically cross-reactive with an epitope in the HVR1 of an HCV strain, the method including bringing into contact a library of peptides as disclosed and an antibody molecule able to bind said HVR1 of an HCV strain, and selecting one or more peptides of the library able to bind said antibody molecule.

The peptide or peptides selected may contain an epitope immunologically cross-reactive with the HVR1 of a plurality of strains of HCV.

5 Such a method may include bringing into contact a library of peptides and a plurality of antibody molecules collectively able to bind the HVR1 of a plurality of strains of HCV. In one embodiment, said plurality of antibody molecules is derived from sera of individuals infected with HCV.

10

As noted, said library may be displayed on the surface of bacteriophage particles, each particle containing nucleic acid encoding the peptide displayed on its surface. Following selection, nucleic acid may be taken from a bacteriophage particle displaying a said selected peptide. Nucleic acid with the sequence of nucleic acid taken from a bacteriophage particle displaying a said selected peptide may be used in production of such a peptide by means of expression (using recombinant DNA technology as standard in the art and
15 discussed further below).

20

A peptide with the amino acid sequence of a said selected peptide may provided in isolated form, e.g. after its production by expression from encoding nucleic acid. As noted
25 further below, one or more peptides in accordance with the

present invention may be provided by peptide synthesis.

A plurality of peptides each with the amino acid sequence of a different selected peptide may provided in isolated form,
5 individually or in a mixture.

A selected peptide or selected peptides may each have an amino acid sequence according to the Formula II given above. All 108 of the different peptides according to Formula II may be
10 provided as a mixture, and furthermore each individually represents an aspect of the present invention. Each peptide of these 108 has a high probability of being cross-reactive with epitopes in the HVR1 of the E2/NS2 protein of a number of strains of HCV, and therefore is particularly useful for
15 obtaining antibodies or otherwise raising an immune response.

A composition according to the present invention may include a plurality of peptides obtainable from a mixture of the 108 peptides of Formula II. Such a composition may include from 2
20 to about 20, 15, 10, 9, 8, 7, 6, 5, 4 or 3 different peptides obtainable from said mixture.

Preferred peptides which may be provided in a mixture or individually include those denoted G31, F78, R9, D6, M122 and
25 H1 of which the amino acid sequences are shown in Figure 7(A).

Preferred mixtures included peptides R9, F78, H1 and D6 ("MIX1"), include peptides M122 and G31 ("MIX2"), or include peptides G31, F78, R9, D6, M122 and H1 ("MIX3").

5 Immunological cross-reactivity of each peptide of the invention with the HVR1 of HCV strains can be assessed experimentally, as exemplified below. Various mixtures of these peptides may also be made and similarly tested, again as experimentally exemplified below.

10

Linear or branched (e.g. MAP) peptides and polypeptides (e.g. fusion molecules including a peptide as discussed) in accordance with the present invention may be made using any of a variety of techniques at the disposal of the ordinary person skilled in the art.

15

Linear or branched peptides may be synthesized using standard peptide chemistry such as by the common method employing Fmoc (Fluorenylmethyl-~~oxycarbonyl~~ossicarbonyl)t-Bu (tert-butyl), as described
20 in Atherton and Sheppard (1989), *Solid Phase Peptide Synthesis, a Practical Approach*, IRL Press, Oxford.

A convenient way of producing a peptide or polypeptide according to the present invention is to express nucleic acid
25 encoding it, by use of the nucleic acid in an expression

system.

Accordingly, the present invention also encompasses a method of making a peptide or polypeptide (as disclosed), the method including expression from nucleic acid encoding the peptide or polypeptide (generally nucleic acid according to the invention). This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the polypeptide. Peptides and polypeptides may also be expressed in *in vitro* systems, such as reticulocyte lysate.

Polynucleotides encoding peptides and polypeptides according to the present invention represent further aspects of the invention.

In one aspect there is provided a polynucleotide encoding a peptide as disclosed. In a further aspect, there is provided a polynucleotide encoding a fusion as disclosed, particularly a HCV E2/NS1 protein including the amino acid sequence of a peptide of the invention in the HVR1 position. In a further aspect, there is provided a recombinant HCV genome including a nucleotide sequence encoding a peptide according to the invention or a fusion as disclosed, particularly a HCV E2/NS1 protein with the relevant peptide amino acid sequence in the

HVR1 position.

In a still further aspect, a polynucleotide is provided which includes a plurality of nucleotide sequences encoding peptides
5 or polypeptides according to the invention. This allows for production of a mixture of peptides or polypeptides in a single expression reaction.

Nucleic acid encoding a peptide or polypeptide according to
10 the present invention may be used in nucleic acid immunisation in order to raise an immune response in a mammal, such as a human individual for a therapeutic or prophylactic purpose, or a non-human mammal for such a purpose or in order to produce antibodies for subsequent manipulation and/or use (e.g. in
15 diagnostic or therapeutic contexts as discussed further below.)

Nucleic acid encoding a peptide or polypeptide according to the present invention may be used in a method of gene therapy,
20 in prevention and/or treatment of HCV infection. This requires use of suitable regulatory elements for expression and a suitable vector for deliver of the expression unit (coding sequence and regulatory elements) to host cells. A variety of vectors, both viral vectors and plasmid vectors,
25 are known in the art, see e.g. US Patent No. 5,252,479 and WO

93/07282. In particular, a number of viruses have been used as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpesviruses, including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art have used disabled murine retroviruses. A variety of adenovirus and adeno-associated viral vectors have been developed. Alternatives to viral vectors include transfer mediated by liposomes and direct DNA uptake and receptor-mediated DNA transfer.

Host cells containing nucleic acid encoding a peptide or polypeptide (or mixture thereof) according to the present invention may themselves be used in therapeutic or prophylactic treatment of individuals for or against HCV infection (i.e. therapeutic treatment of an individual with an HCV infection or prophylactic treatment of an individual prior to HCV infection).

Nucleic acid is generally provided as DNA or RNA, though may include one or more nucleotide analogues, and may be wholly or partially synthetic. Nucleic acid molecules and vectors according to the present invention may be provided in isolated and/or purified form, e.g. in substantially pure or homogeneous form. The term "isolate" may be used to reflect all these possibilities. Where a DNA sequence is specified,

e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.

5 Where it is desired to express a peptide or polypeptide from encoding nucleic acid, the nucleic acid includes appropriate regulatory control sequences. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments,
10 polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring
15 Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current
20 Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1992.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host
25 cells include bacteria, eukaryotic cells such as mammalian and

yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others. A
5 common, preferred bacterial host is *E. coli*.

A further aspect of the present invention provides a host cell containing nucleic acid as disclosed herein. The nucleic acid of the invention may be integrated into the genome (e.g.
10 chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques. The nucleic acid may be on an extra-chromosomal vector within the cell.

15 A still further aspect provides a method which includes introducing the nucleic acid into a host cell. The introduction, which may (particularly for *in vitro* introduction) be generally referred to without limitation as "transformation", may employ any available technique. For
20 eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may
25 include calcium chloride transformation, electroporation and

transfection using bacteriophage. As an alternative, direct injection of the nucleic acid could be employed. Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as
5 is well known in the art.

The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more
10 likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded peptide or polypeptide is produced. If the peptide or polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the
15 culture medium. Following production by expression, a peptide or polypeptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional
20 components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below).

A peptide or polypeptide according to the present invention
25 may be used as an immunogen or otherwise in obtaining binding

antibodies. Antibodies are useful in purification and other manipulation of polypeptides and peptides, diagnostic screening and therapeutic contexts, including passive immunisation. This is discussed further below.

5

According to a further aspect of the present invention there is provided a method of obtaining one or more antibody molecules containing a binding site able to bind an epitope in the HVR1 of a plurality of HCV strains, the method including
10 bringing into contact a population of antibody molecules and a peptide according to the present invention, and selecting one or more antibody molecules of the population able to bind said peptide.

15 The method may involve bringing the population of antibodies into contact with a plurality of peptides according to the invention.

As noted, the peptides may be provided in a fusion with
20 additional amino acids.

The peptide or peptides may be administered to a non-human mammal to bring them into contact with a population of antibody molecules produced by the mammal's immune system,
25 then one or more antibody molecules able to bind the peptide

or peptides may be taken from the mammal, or cells producing such antibody molecules may be taken from the mammal.

The mammal may be sacrificed.

5

If cells are taken from the mammal, antibody molecules may be taken from said cells or descendants thereof. Such descendants in particular may include hybridoma cells.

- 10 Instead or as well as immunising an animal, a method of obtaining antibodies as disclosed may involve displaying the population of antibody molecules on the surface of bacteriophage particles, each particle containing nucleic acid encoding the antibody molecule displayed on its surface.
- 15 Nucleic acid may be taken from a bacteriophage particle displaying an antibody molecule able to bind a peptide or peptides of interest, for manipulation and/or use in production of the encoded antibody molecule or a derivative thereof (e.g. a fusion protein, a molecule including a
- 20 constant region or other amino acids, and so on). Instead of using bacteriophage for display, ribosomes or polysomes may be used, e.g. as disclosed in US-A-5643768, US-A-5658754, WO95/11922.

- 25 Antibody molecules may be provided in isolated form, either

individually or in a mixture. A plurality of antibody molecules may be provided in isolated form.

Preferred antibodies according to the invention are isolated,

5 in the sense of being free from contaminants such as

antibodies able to bind other polypeptides and/or free of serum components. Monoclonal antibodies are preferred for

some purposes, though polyclonal antibodies are within the scope of the present invention. Indeed, polyclonal mixtures

10 able to bind one or more peptides or polypeptides according to the present invention are preferred in some embodiments, as discussed. Thus, the present invention in a further aspect is directed to a mixture of different antibodies able to bind one or more peptides or polypeptides according to the invention.

15 Such a mixture may be provided in a composition including at least one additional component, such as a pharmaceutically acceptable excipient or vehicle.

The present invention also extends to methods of obtaining

20 and/or raising antibodies to one or more peptides or

polypeptides of the invention. Such methods may include

administering a peptide or polypeptide or mixture of peptides or polypeptides to a mammal in order to raise an antibody

response. In a therapeutic or prophylactic context the mammal

25 may be human or non-human. For the production of antibodies

or antibody-producing cells to be isolated and used for any of a variety of purposes, a step of sacrificing a non-human mammal may be included. Such a non-human mammal may be for example mouse, rat, rabbit, dog, cat, pig, horse, donkey, goat, sheep, camel, Old World monkey, chimpanzee or other primate. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to peptide or polypeptide of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, Nature, 357:80-82, 1992).

The production of polyclonal and monoclonal antibodies is well established in the art. Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-239400. Humanised antibodies in which CDRs from a non-human source are grafted onto human framework regions, typically with the alteration of some of the framework amino acid residues, to provide

antibodies which are less immunogenic than the parent non-human antibodies, are also included within the present invention. A hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic
5 mutation or other changes , which may or may not alter the binding specificity of antibodies produced. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

10 As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using bacteriophage which display functional immunoglobulin binding domains on
15 their surfaces - for instance see W092/01047 - or ribosomes/polysomes as noted above. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed using sequences obtained
20 from an organism which has been exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be
25 construed as covering any binding substance having a binding

domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimics that of an antibody enabling it to bind an antigen or epitope.

Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')₂ fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.

The reactivities of antibodies on a sample (e.g. in a diagnostic test) may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate
5 detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter
10 molecule.

One favoured mode is by covalent linkage of each antibody with an individual fluorochrome, phosphor or laser dye with spectrally isolated absorption or emission characteristics.
15 Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.

Other reporters include macromolecular colloidal particles or
20 particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which
25 catalyse reactions that develop or change colours or cause

changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.

The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.

Antibodies according to the present invention may be used in screening for the presence of a peptide or polypeptide, for example in a test sample containing cells or cell lysate as discussed, and may be used in purifying and/or isolating a peptide or polypeptide according to the present invention, for instance following production of the polypeptide by expression from encoding nucleic acid therefor.

Antibodies are also useful in prophylaxis, by way of passive immunisation, and in therapy. Where antibodies are to be administered, it may be preferable to include a mixture of antibodies, such as antibodies collectively cross-reactive

with a plurality of peptides according to the present invention.

Antibodies which bind a peptide in accordance with the present invention may themselves be used as immunogens in the production of anti-idiotypic antibodies. These may be used to mimic a peptide epitope in raising an immune response in an individual, e.g. for therapeutic and/or prophylactic purposes.

10 An antibody may be provided in a kit, which may include instructions for use of the antibody, e.g. in determining the presence of a particular substance in a test sample. One or more other reagents may be included, such as labelling molecules, buffer solutions, elutants and so on. Reagents may
15 be provided within containers which protect them from the external environment, such as a sealed vial.

Diagnostic methods make use of biological samples from individuals that may contain one or more HCV strains.

20 Examples of biological samples include fluid such as blood, plasma, serum, urine and saliva, and tissue samples.

There are various methods for determining the presence or absence in a test sample of a particular peptide or
25 polypeptide, including methods wherein the polypeptide to be

detected is an antibody.

A sample may be tested for the presence of a specific binding member such as an antibody (or mixture of antibodies) directed
5 to one or more peptides of the invention.

Peptides according to the present invention may be used to determine the presence or absence of antibodies against HCV strains in test samples, by assessment of binding the peptides
10 to anti-HCV E2HVR1 antibodies if present in the sample.

In theory it may be possible to identify the presence in a sample of a binding partner for a specific binding member such as an antibody (or mixture of antibodies) directed to one or
15 more peptides of the invention. However, to date no-one has succeeded in isolating HCV virions from a human sample. In the future, should it prove possible to identify HCV virions in human samples and/or detect such virions immunologically, peptides of the invention and particularly antibodies directed
20 thereto will be useful in such detection.

For detection of antibodies to HCV, a biological or other sample may be tested by being contacted with one or more peptides of the invention under appropriate conditions for
25 specific binding, before binding is determined, for instance

using a reporter system as discussed. Where a panel of peptides is used, different reporting labels may be employed for each peptide so that binding of each can be determined.

5 A specific binding member such as a peptide may be used to isolate and/or purify its binding partner antibody from a test sample, to allow for sequence and/or biochemical analysis of the antibody. Amino acid sequencing is routine in the art using automated sequencing machines.

10

A typical immunoassay may involve incubating a test sample with peptides according to the invention under conditions to allow formation of immune complexes if an appropriate antibody is present in the sample, and detecting the presence or

15

absence of immune complex.

As noted, although not technically feasible at the moment, in principle antibodies according to the present invention may be used to determine the presence or absence of HCV strains in
20 test samples, by assessment of binding of the antibodies to E2HVR1 epitopes if present in the sample.

A typical immunoassay may involve incubating a test sample with peptides or anti-idiotypic antibodies according to the
25 invention under conditions to allow formation of immune

complexes if an appropriate antibody is present in the sample, and detecting the presence or absence of immune complex.

A sample may be tested for the presence of an antibody
5 directed to one or more peptides of the invention, using one or more such peptides (or polypeptide including such peptide) or one or more anti-idiotypic antibodies.

10 A biological or other sample may be tested by being contacted with a peptide or polypeptide or anti-idiotypic antibody under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system as discussed.

The detection of formation of a binding complex in an
15 immunoassay in accordance with the present invention may be performed using any available technique without limitation to the scope of the invention. Some suitable techniques are described above with reference to antibody labelling. Assays may involve immobilising antibody or peptide, as the case may
20 be, on a suitable solid phase or support, such as latex particles, magnetic or non-magnetic beads, a membrane, chip, plastic, metal, silicon or glass surface, or any other suitable material at the disposal of the skilled person.

Detection may be qualitative or quantitative. One or more
25 appropriate controls may be included, in accordance with

standard practice.

As noted already, peptides, polypeptides, antibodies and nucleic acid in accordance with the present invention may be formulated into compositions, and are useful in pharmaceutical contexts. These compositions may include, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, the

active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

10 Branched peptides, such as MAP (Tam, J.P, 1988) may be used for the preparation of immunogens, either alone or linked to an appropriate carrier.

A linear peptide for use in raising an immune response may also be linked to an appropriate carrier. Various methods of coupling peptides to other molecules are known in the art, including disulphide forming reagents (where the peptide includes a cysteine - or a cysteine is added to the peptide for this purpose), thio-ether forming coupling agents and so on. Carriers include human serum albumin (HSA), tetanus toxoid, other rather large proteins that have reasonable half-lives under physiological conditions, and stable non-proteinaceous molecules such as polysaccharides and copolymers of amino acids.

An adjuvant may be included, such as alum, oil-in-water emulsions or Freund's Adjuvant (Complete or Incomplete). Cytokines may be used to potentiate immunogenicity of the peptide or polypeptide composition.

5

Mimotope sequences may be cloned into the context of the HCV envelope (E2) protein in order to use the natural folding environment for correct presentation of the epitope or epitopes to the immune system.

10

Naked DNA may be used for immunization (see e.g. Cohen, J, 1993), and one or more mimotope sequences may be cloned into suitable vectors (see e.g. Major et al., 1995). Naked DNA may be delivered using direct injection or by use of gene-guns (Yang et al., 1990) or any other suitable technique.

15

Whether it is a polypeptide, antibody, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration may be in an immunogenic amount, that is sufficient to raise an immune (particularly antibody) response in the individual, or in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy). A prophylactic effect is

20

25

sufficient to potentiate the immune response of an individual to a subsequent challenge with HCV, E2HV polypeptide, or HVR1 peptide, or to a subsequent infection with HCV, preferably in the latter case (HCV infection) to sufficient to antagonise the infection, wholly or partially. Most preferably the effect is sufficient to prevent the individual from suffering one or more clinical symptoms as a result of subsequent HCV infection, and/or protect the individual from hepatitis C. A therapeutic effect is sufficient to potentiate the immune response of an individual to pre-existing HCV infection, preferably sufficient to antagonise the infection, wholly or partially. Most preferably the effect is sufficient to ameliorate one or more clinical symptoms, and/or cure the hepatitis C and/or reduce viral titre in the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

Further aspects of the invention provide methods of treatment including administration of a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, as provided, pharmaceutical compositions including such a

5 peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, and use of such a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, in the manufacture of a medicament for administration, for example in a method of making a medicament or pharmaceutical

10 composition including formulating the specific binding member with a pharmaceutically acceptable excipient.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially

15 dependent upon the condition to be treated and the availability of alternative or additional treatments.

One aspect of the present invention provides use of a peptide as disclosed in the manufacture of a medicament for raising in

20 a mammal antibodies able to bind HCV HVR1 epitopes.

Another aspect provides a method of immunising a mammal against HCV infection, the method including administering a peptide or mixture of peptides to the mammal.

A still further aspect provides a method of (passively) immunising a mammal against HCV infection, the method including administering an antibody according to the invention to the mammal, or a mixture of antibodies.

5

Similarly, further aspects of the invention provide a method of treating a mammal with an HCV infection, the method including administering a peptide according to the invention, or a mixture of peptides, or an antibody, or a mixture of antibodies, to the mammal.

10

The antibodies may be anti-idiotypic antibodies.

15

Aspects and embodiments of the present invention will now be illustrated further and experimentally exemplified with reference to various figures. Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art.

20 In the figures:

Figure 1(A) illustrates derivation of the consensus pattern of the 234 natural variants of the HCV HVR1 sequences used in this work. Non shaded residues within the box account alone
25 for about 80% of the observed variability. Residues are

listed in decreasing order of observed frequency from top to bottom.

Figure 1(B) shows the composition in the initial HVR1 peptide library which was displayed on bacteriophage.

Figure 2 shows reactivity of phage pools yielded by the first round of affinity selection to antibodies present in the selecting sera. For each serum sample ($\sigma 1$, $\sigma 4R$, $\sigma 3$, $\sigma 2P$, $\sigma 2R$, $\sigma 3R$ and σN) antibody recognition of the phage pools (pool 1, 4R 3, 2P, 2R, 3R and N), wild type phage (wt) and the unselected library (HVR1 lib) was measured. Average values (A_{405nm}) from two independent experiments have been determined.

Figure 3 shows distribution of HCV-specific phage selected from the HVR1 library as function of their frequency of reactivity with sera from infected patients. Binding is shown for phage enriched by one (top panel) or two (bottom panel) cycles of affinity selection to antibodies present in twenty human sera different from those used for the selections. For each serum, average values (A_{405nm}) from two independent experiments have been determined on the selected phage and on wild type phage. Values were considered statistically significant when differing more than $3\sigma_{max}$ ($p < 0.003$) from the

background signal observed for the wild type phage. Each histogram represents the number of phage (shown on the vertical axis) reacting with the indicated number of sera expressed as percentage over total number of tested samples (horizontal axis).

Figure 4 shows that the selected mimotopes are frequently recognized by antibodies present in human sera from HCV infected patients. Binding of the selected mimotopes to antibodies present in human sera was detected by ELISA on immobilised phage. Mimotopes' names are indicated at the top of each column. For each serum (indicated on the left of each row), average values (A_{405nm}) from two independent experiments have been determined. Results are expressed as the difference between the average value of the tested phagotope and that of wild type phage. Positive values are indicated in bold. Values were considered statistically significant when differing more than $3\sigma_{max}$ ($p < 0.003$) from the background signal observed for the wild type phage. The frequency of reactivity of each mimotope and that resulting from the sum of the reactivities observed with all four mimotopes are shown at the bottom of each panel.

Figure 4(A) shows reactivity of selected mimotopes with the panel of twenty HCV patients' sera used for the screening

step.

Figure 4(B) shows reactivity of selected mimotopes with an additional panel of sera from HCV-infected viremic patients.

5

Figure 4(C) shows reactivity with sera from non viremic patients that were scored positive for anti-HCV antibodies using commercially available kits.

10 Figure 5 shows correlation between the S-score and the frequency of reactivity of the selected mimotopes. The straight line represents the linear least square fit of the data. The correlation coefficient is 0.79.

15 Figure 6 shows that the selected mimotopes are antigenic mimics of a large number of naturally occurring HVR1.

Antibodies from a pool of sera from HCV infected patients were immunopurified on MAPs reproducing the sequence of selected mimotopes (indicated at the top of the figure). Reactivity of
20 equal amounts of the immunopurified antibodies was measured by ELISA on a representative panel of HVR1 sequences synthesized as MAPs (indicated in the left column). Average values from two independent experiments were determined. Values were considered statistically significant when two criteria were
25 contemporarily fulfilled: (1) values were differing more than

$3\sigma_{\max}$ ($p < 0.003$) from the background signal observed on two unrelated peptides; (2) values were differing more than $3\sigma_{\max}$ ($p < 0.003$) from the average signal observed using ten sera from non infected individuals on each peptide representing a

5 natural HVR1. Grey boxes indicate signals differing from those observed on the unrelated MAPs between 0.15 and 0.5 OD (405nm); black boxes indicate values differing more than 0.5 OD (405nm). The level of cross-reactivity of each pool of immunopurified antibodies is indicated at the bottom of each

10 column.

Figure 7 shows correlation between mimotope sequence and cross-reactivity.

15 Figure 7(A) shows the sequences of the mimotopes used in the analysis.

Figure 7(B) shows correlation between the S-score of the mimotopes and the cross-reactivity of immunopurified human

20 antibodies with a panel of 43 natural HVR1 sequences. The straight line represents the linear least square fit of the data. The correlation coefficient is 0.86.

Figure 8 shows that the selected mimotopes are immunogenic

25 mimics of a large number of naturally occurring HVR1.

Reactivity of sera from mice immunised with single HVR1 mimotopes (Figure 8(A)) and mixtures of mimotopes (Figure 8(B)) in the form of MAP was assayed by ELISA on the panel of natural HVR1 sequences (indicated in the left column).

5 Immunizing mimotopes are shown in the first row. MIX1 includes mimotopes R9, F78, H1 and D6; MIX2 contains M122 and G31 peptides; MIX3 is composed of all six MAPs. Titres (defined as the dilution required to obtain half maximal signal in ELISA on the homologous peptide) are shown in the
10 second row. Sera were diluted 1:100. Average values from two independent experiments have been determined. Values were considered statistically significant when differing more than $3\sigma_{\max}$ ($p < 0.003$) from the background signal observed on two unrelated peptides. Grey boxes indicate signals differing
15 from those observed on the unrelated MAPs between 0.15 and 0.5 OD (405nm); black boxes indicate values differing more than 0.5 OD (405nm). The level of cross-reactivity of each serum is indicated at the bottom of each column.

20 Figure 9 illustrates plasmids employed in in vivo nucleic acid immunisation experiments described in Example 6.

EXAMPLE 1 - Design and construction of a specialised phage library mimicking the HVR1 variability

A multiple sequence alignment of 234 unique HVR1 sequences extracted from the sequence databases was made to characterise the variation in residue composition at each of the N-terminal 27 positions of the HCV E2 glycoprotein. A sequence pattern emerged from this analysis (Figure 1A) allowing the definition of a degenerate consensus sequence. A synthetic repertoire of HVR1 sequences was designed to contain such conserved constraints while reproducing the observed natural variability in the remaining positions.

10

A "consensus-profile" accounting for approximately 80% of the total sequence variability was derived by selecting the most frequent residues at each position. When similar amino acids were present at a given position, only one was chosen as representative of the variability, preferring those residues which could more effectively form interactions. For example, in position 5 both Ser and Thr are present in the natural repertoire, but only Thr was selected to design the library (Figure 1). In some cases, a residue not present in the consensus was included in the library to better mirror the overall variability. For example, Thr was included in position 3 to account for the presence of Ser, Thr, Asn in the natural repertoire of HVR1s.

25 The resulting final consensus profile (Figure 1B) has a

complexity of 9×10^7 very close to the upper practical limit (about 10^8) of current DNA cloning and transformation techniques. The amino acid most frequently observed in the natural repertoire was always included with the exception of position 1, (where Gln and Thr were selected although Glu is the most frequently observed amino acid). Eight positions (2, 6, 7, 16, 19, 20, 23 and 26) were kept constant given the high local sequence conservation throughout the 234 natural HVR1 variants. Noteworthy also is the total absence of negatively charged residues. With the exception of position 1, where Gln was chosen to represent the His, Glu, Asp, Gln, Asn group, no acidic residues were present within the 80% fraction. Qualitatively, the profile can be described as a generally more variable central region flanked by N-terminal and C-terminal tails containing conserved elements.

Construction of the library proceeded by cloning a degenerated synthetic oligonucleotide as a fusion to the 5' end of the gene coding for the major coat protein (pVIII) in a phagemid vector for M13 display (see Materials and Methods). About 2×10^8 independent transformants were obtained. To verify the quality and complexity of the library (HVR1 library), the inserts of fifty-six randomly chosen individual clones were sequenced. This analysis led to the following results:

- (1) all clones displayed different sequences;
- (2) 63% of the clones contained full-length inserts while the remaining ones had small deletions;
- (3) none of the sequenced clones encoded for peptides
- 5 corresponding to known HVR1 from viral isolates, searched on 15 March 1998.

From these data it was inferred that the library has a complexity close to the number of individual transformants.

10 *EXAMPLE 2 - Identification of HVR1 mimotopes frequently reacting with HCV patients' sera*

The more complex and diverse the repertoire of antibodies used

15 for the selection, the higher should be the probability to enrich phage recognised by many different antibodies against HVR1 epitopes. Sera from chronically infected, viremic patients appear to meet these requirements as these individuals have a rather long history of viral persistence,

20 during which a large number of HCV variants have been generated and have challenged the immune system, presumably leading to the accumulation of a highly heterogeneous population of anti-HVR1 antibodies.

25 Eight sera from chronic patients infected by viruses of five

different genotypes: 1a, 1b, 2a, 2b, 3a (Simmonds et al., 1993) were used to perform six affinity selections of the HVR1 library (Table 1). As control, a serum from a non infected individual was also used. Pools of phage obtained from all
5 seven selections were amplified and tested for their reactivity to each of the selecting sera in ELISA. The results of this experiment showed a significant enrichment of phage recognised by the selector antibodies, as evidenced by the increase in reactivity with respect to the unselected
10 library (Figure 2). In most cases, phage pools enriched by HCV sera reacted with more than one patient's serum. Peptides recognised by antibodies unrelated to HCV infection were also enriched from the library. In fact, the pool of phage selected with the control serum has a higher reactivity with
15 this serum than the unselected library (Figure 2). However, patients' sera drove selection toward HCV-related mimotopes as no reactivity to phage pools enriched by HCV sera was detected using sera from healthy individuals (Figure 2 and data not shown).

20

To gain insight into the frequency of reactivity of the selected mimotopes with different patients' sera, forty individual clones from two pools (4R and 2R, Table 1) were randomly chosen and tested for their reactivity in ELISA with
25 a panel of twenty sera from HCV infected patients different

from those used for the selection. An equivalent number of sera from non-infected healthy controls were used to assess the specificity for anti-HCV antibodies. Twenty-four clones turned out to be HCV-specific. Their distribution as a function of their frequency of reactivity with patients' sera is reported in Figure 3 (upper panel). Among them, phage reacting with more than one serum were identified; some of these were recognised by up to 55% of the tested sera.

10 To further improve the isolation of mimotopes reacting with many different anti-HVR1 antibodies, the enriched phage pools were subjected to a second round of affinity selection using patients' sera different from those used for the first round. In this way nine new pools were generated (Table 1) and

15 analysed by ELISA. As before, a general increase in reactivity with the selector antibodies was observed. In addition, all second round phage pools reacted more frequently than those selected in the first round with a panel of sera from HCV-infected patients different from those used for

20 either selection, reflecting a higher recognition frequency of the isolated peptides. This was confirmed by comparing the reactivity with HCV sera of clones randomly chosen among those eluted after one round of affinity selection (Figure 3, upper panel) and those obtained by re-selecting them with a second

25 different serum (Figure 3, lower panel). Not only the

frequency, but also the distribution of reactivity appeared to be significantly different after the second selection step. While recognition of phage from the first selection appears to be rather scattered, clones isolated through two rounds of selection show a bell-shaped distribution of their frequency of reactivity with an average value of 60% (Figure 3, lower panel), indicating that the whole phage population had indeed acquired more of the desired binding properties. It was decided to omit additional selection cycles to avoid introduction of a bias toward biologically favoured phage during amplification.

A total of one hundred and seventy one clones reacting exclusively with HCV sera were identified by screening all second-round pools. Their distribution as a function of the recognition frequency by HCV sera mirrored that of the subset displayed in Figure 3, lower panel, with the best clones reacting with 80% of the tested samples. More importantly, the profiles of reactivity of the selected mimotopes highlight another relevant feature. Despite their quantitative similar overall frequency of recognition by the HCV sera, different clones display a characteristic pattern of reactivity with the net result that few mimotopes can score for the presence of anti-HVR1 antibodies in all tested sera (Figure 4A).

Next, it was verified whether the observed high frequency of recognition by HCV sera was limited to the tested patients' population or whether it reflected an intrinsic property of the selected mimotopes. For this purpose another set of sera from infected patients was assayed by ELISA revealing that both the frequency of reactivity of each individual phage and the total coverage of the sera remained unaltered (Figure 4B).

HCV infected individuals who have resolved the infection most likely came in contact with a lower number of viral variants and presumably developed a narrower spectrum of variant-specific anti-HVR1 antibodies than chronically infected patients. This is supported by the finding that sera from the former population react with synthetic peptides reproducing the HVR1 of natural isolates much more rarely than those of chronically infected viremic patients (Scarselli et al., 1995). Therefore, non viremic sera could constitute a better and more stringent test for assaying the cross-reactivity of HVR1 mimotopes with different anti-HVR1 antibodies. Some of the selected mimotopes were thus tested against forty-one samples from HCV seropositive individuals who were repeatedly found negative for the presence of viral RNA in the blood. Again, the mimotopes reacted with many of these sera albeit at a lower frequency than that observed with sera from viremic patients (compare Figures 4(A), 4(B) and 4(C)). These data

provide an indication of the ability of the selected mimotopes to cross-react with a large number of different anti-HVR1 antibodies.

5 *EXAMPLE 3 - Determination of a relationship between the sequence of the selected HVR1 mimotopes and their frequency of reactivity with HCV sera.*

10 The inventors wished to verify whether the amino acid sequence of the selected clones correlates with their frequency of reactivity. No obvious pattern arises from a visual comparison of the sequences so it was decided to analyse separately the sequence patterns of the least and most frequently reacting clones.

15

Defined as "weak" were the 24 clones that only reacted with less than 3 sera and defined as "strong" were the 27 reacting with more than 11 sera. The amino acid frequencies at each position of weak and strong clones are listed in the Materials
20 and Methods section below, and in Table II.

There is a clear trend for some positions to be occupied by different amino acids in the sets of weak and strong clones and this allowed us to heuristically define a position-based
25 scoring system described in Materials and Methods (see below).

The higher is the score of a clone (S-score) the more similar its sequence is to those of the strong clones and the more different from those of the weak ones. As shown in Figure 5, the S-score correlates reasonably well (correlation coefficient = 0.75) with the experimentally determined frequency of reactivity of each clone. It should be emphasised that the S-score was calculated using only the sequences of the "weak" and "strong" clones (51 out of 171), but it correlates well with the frequency of reactivity of all clones. Interestingly, a nearly identical result (correlation coefficient = 0.72) can be obtained using only 6 positions where the residue preference of the weak and strong mimotopes differ most (positions 3, 11, 18, 21, 22, 24).

15 *EXAMPLE 4 - The HVR1 mimotopes antigenically mimic a large number of HVR1 variants from HCV isolates.*

The inventors set to measure the cross-reactivity of human antibodies which recognise the mimotopes, with sequences representing naturally occurring HVR1.

For this purpose the mimotopes were used as immunoabsorbents to purify the specific antibodies from the bulk of anti-HVR1 present in infected patients' sera. Mimotopes R9, F78, M122, R6, B14, G31, H1 and D6 (Figure 7) were chosen for these experiments because they were among those which displayed the

highest frequency of reactivity with the HCV sera. Mimotope N5 which was recognised by a significantly lower percentage of HCV sera than the average "good" mimotopes (35% and 60-80%, respectively) was also used.

5

Although some lymphocyte cell lines have been shown to support limited replication of HCV (Shimizu et al., 1992), these systems are not suited for viral propagation and for a detailed study of the cross-reactivity of anti-HVR1 antibodies. Therefore, the cross-reactivity of the immunopurified antibodies on a panel of synthetic peptides reproducing natural HVR1 variants which approximately cover the observed sequence variability was determined.

10 To this end, a multi-dimensional cluster analysis (Casari et al., 1995) was performed on the same set of 234 aligned natural HVR1 sequences used for the construction of the library. Out of these, forty-three sequences nearly homogeneously distributed over the HVR1 "sequence space" were
15 chosen (see Materials and Methods below) and synthesised as multiple antigenic peptides (MAP; Tam, J.P, 1988; Pessi et al., 1990). A pool of eight sera from infected patients collectively reacting with the entire panel of forty-three MAPs was used as a source of antibodies. The immunopurified
20 antibodies displayed the same reactivity to the mimotope used
25

for the purification compared to the total serum. In contrast, no reactivity to a recombinant HCV core antigen or to the antigens included in a commercially available kit (see below in Materials and Methods) was retained after purification thus testifying to the efficiency and the specificity of the purification.

All immunopurified antibodies reacted with a significant number of natural HVR1 sequences with mimotope R9 yielding antibodies cross-reacting with 79% of natural HVR1 (Figure 6). As most immunopurified antibodies also displayed some non-overlapping reactivities to the natural sequences, an even higher level of overall cross-reactivity (88%) can be reached by adding up the individual contributions of antibodies purified from only three different mimotopes (R9, F78 and M122, Figure 6). From these data it was concluded that a limited set of HVR1 mimotopes can antigenically mimic a large number of natural HCV HVR1 variants.

Antibodies immunopurified by mimotopes with higher S-score, and consequently with a higher frequency of reactivity, also showed to be more cross-reactive. Eight mimotopes were used and, as shown in Figure 7B, the correlation between this sequence related score and the cross-reactivity of the corresponding antibodies is very good ($r = 0.86$; Figure 7B).

EXAMPLE 5 - The HVR1 mimotopes induce antibodies recognising many natural HVR1 variants.

A problem prior to the present work was the generation of immunogens able to induce antibodies cross-reacting with the largest number of HCV HVR1 natural variants. The immunogenic potential of some of the best HVR1 mimotopes (R9, F78, M122, G31, H1 and D6) was investigated by injecting them in mice both as whole purified phage and, outside of the original context in which they were selected, as MAPs.

MAPs turned out to be much more potent immunogens presumably due to the insufficient loading of HVR1 peptides on each phage as indicated by mass spectrometry analysis (less than 1% of the total pVIII content). Some variability in the efficiency of immunization was observed between the mimotopes as shown by the difference in titre, with F78 being able to induce antibody titres higher than 1/100,000 as measured by ELISA on the same peptide used for the immunisation (Figure 8A). Anti-HVR1 mimotope sera were then tested for their ability to recognise heterologous HVR1 variants by ELISA on the panel of forty-three MAPs reproducing HCV sequences from natural isolates. Most of these MAPs were recognised by the immune sera (Figure 8A), while no reactivity was observed on unrelated control peptides.

The cross-reactivities of the sera of mice immunised with mimotopes did not rank as that of human antibodies immunopurified with the same mimotopes. However, mimotope N5, which showed significantly lower levels of reactivity in both types of assays, revealed to be a much less efficient immunogen, leading to an anti-HVR1 response able to recognize only a minority of the natural HVR1 sequences (Figure 8A).

The extent of cross-reactivity of the immune sera generally reflects the immunogenicity of the individual MAPs as, in most cases, a higher titer corresponds to a higher level of cross-reactivity (Figure 8A). Nevertheless, titer alone cannot always explain the difference in cross-reactivity and in the pattern of reactivity displayed by the mimotope induced sera as clearly shown in the case of the anti-G31 serum which has a lower titer than the anti-F78, but reacts with a larger number of natural HVR1 peptides. Similarly, the anti-D6 serum displays the same level of cross-reactivity of the anti-R9 despite a three fold lower titer (Figure 8A).

The pattern of reactivity displayed by each antiserum is only partially overlapping with that of the others, and, in some cases, unique reactivities were observed. As a consequence of this feature of the induced sera, by adding up all the reactivities, almost all natural HVR1 peptides are recognized

(91%, Figure 8A). This observation is a significant improvement toward the goal of generating broadly reacting antibodies, provided one can obtain a similar increase in cross-reactivity a single immunization with a cocktail of mimotopes. Therefore, three groups of Balb/c mice were immunised with mixtures of mimotopes. Mixture 1 contained mimotopes R9, F78, H1 and D6; mixture 2 was composed of mimotopes M122, and G31, while mixture 3 comprised all six mimotopes. All three mixtures were immunogenic, and induced highly cross-reactive antisera (Figure 8B). Each of the three antisera displayed the same or an even higher cross-reactivity than that measured by adding up the reactivities of the antisera induced by each of the mimotopes included in the mixture (84% vs 84% for MIX1, 84% vs 81% for MIX2 and 95% vs 91% for MIX3, Figure 8B). The titers of these sera although high, were not better than those obtained with individual MAPs. It was therefore concluded that the ability of inducing highly cross-reacting response is not simply a consequence of the efficiency of the immunisation.

20

MATERIALS AND METHODS

Human sera

25 Human sera from HCV-infected patients and from healthy

individuals were characterised for the presence of antibodies to HCV by a second-generation HCV ELISA test system (Ortho-HCV ELISA, Ortho Diagnostic Systems, Bersee, Belgium) and by a first generation dot blot immunoassay (RIBA-HCV test, Chiron Co., Emeryville, CA). The presence of HCV RNA was detected by nested reverse transcription-PCR using conserved primers localised in the 5' non-coding region of the viral genome and total RNA extracted from 100 μ l of serum as previously described (Silini et al., 1995).

Construction of the HVR1 library

To back-translate the consensus profile described above with reference to Figure 1B into the corresponding nucleotide sequence, the *E. coli* codon usage table was employed selecting codons most frequent in highly expressed genes. To facilitate insertion of the library into the phagemid vector two additional constant sequences containing the recognition sites for the restriction enzymes PacI and NotI were added 5' and 3' to the 81bp segment, respectively giving a total of 116 bp. Absence of NotI and PacI restriction sites in the backtranslation of the consensus profile was verified by computer-assisted sequence analysis. For the chemical synthesis a codon-based "split-and-pool" method (Cormack et al., 1993) was applied in order to keep both library

composition and complexity at the desired level. The 116 bp oligonucleotides were amplified with primers complementary to the flanking constant sequences in a 9600 DNA Thermal Cycler (Perkin-Elmer Cetus, Foster City CA). The PCR product was

5 digested with PacI and NotI enzymes and gel-purified. The recovered DNA fragment was cloned between the PacI and NotI sites of the pel8PN phagemid vector (a derivative of pc89; Felici et al., 1991) downstream of the pelB secretion leader and upstream of the entire gene VIII coding sequence.

10 Recombinant phagemids were electroporated into DH10B competent cells. Since DH10B cells cannot be infected by filamentous phage and do not allow for blue/white selection, transformed cells were collected and plasmid DNA was prepared. This DNA was used to transform by electroporation XL1-blue competent

15 cells. Ampicillin resistant colonies were scraped from the plates and resuspended in LB/100 μ g ampicillin/ml and 10% (v/v) glycerol. A portion of this bacterial suspension was inoculated into six litres of LB medium containing 100 μ g ampicillin/ml at 0.05 O.D._{600nm} and grown with vigorous shaking

20 until 0.25 O.D._{600nm} was reached. The culture was then superinfected with M13K07 helper phage and grown for additional five hours to obtain the phage particles in the supernatant. The phage were precipitated twice with polyethylene glycol and purified by equilibrium centrifugation

25 in CsCl as described (Felici et al., 1991).

DNA-sequencing was performed as described (Bartoli et al., 1996) using an Applied Biosystem 373 DNA sequencer.

Library affinity selection

5

ELISA multiwell plates (Nunc Maxisorp, Roskilde, Denmark) were coated overnight at 4°C with 0.5 µg/ml of anti-human (Fc-specific) polyclonal Ab (Immunopure goat anti-human IgG Fc-specific; Pierce, Rockford, IL) in 50 mM NaHCO₃ pH 9.6. The plates were washed with PBS/0.1% Tween 20 (washing buffer) and incubated for 1 hr at 37°C with 100 µl/well of blocking buffer (5% non fat dry milk, PBS/0.05% Tween 20). 1 µl of human serum diluted 1:100 in PBS /0.1% BSA was added to each well and incubated overnight at 4°C. After washing, 10¹² particles of U.V. killed M13K07 diluted in PBS/0.1% Tween 20, 0.01% BSA, were then added to each well and incubated for 4 h at 4°C. After this pre-incubation, 10¹² particles/well of HVR1 library were added and incubated overnight at 4°C. Unbound phage were removed and several rounds of washing were

20 performed. Bound phage were eluted with 200 µl of elution buffer (0.1M HCl adjusted to pH 2.5 with glycine, 1 mg/ml BSA) and neutralised with 2M Tris-HCl pH 9. Eluted phage were titrated by infection of XL1-blue bacteria and the percentage of clones containing a productive insert was determined by
25 plating infected bacteria on X-gal/IPTG indicator plates

(Felici et al., 1991). After amplification (see above) enriched phage were subjected to a second cycle of affinity selection following the same procedure.

5 *Sequence analysis of the mimotopes and definition of the S-score*

Out of a total of 193 selected clones, 171 showed no point mutation (with respect to the original library design) or deletions and were divided in three classes: 24 weak clones (reacting with less than 3 out of the 20 tested sera), 27 strong clones (reacting with at least 12 sera) and intermediate (the remaining clones).

15 For each amino acid at position i of a 27-mer amino acid sequence, we call $F_s(i, aa)$ and $F_w(i, aa)$ the observed frequency of the same amino acid in position i of the set of strong and weak clones, respectively.

20 The frequency values are shown in Table II.

$S\text{-score}(i)$ was then defined as the difference between the square roots of $F_s(i, aa)$ and $F_w(i, aa)$. The sum over the all 27-mer sequence of $S\text{-score}(i)$ is our sequence based $S\text{-score}$.

25 In practice:

$$S\text{-score} = \sum_i (\sqrt{F_s(i, aa)} - \sqrt{F_w(i, aa)})$$

where aa is the observed amino acid in position i of the sequence for which the S-score is calculated. The square root of the frequencies was used to amplify differences. For clones where a point mutation or deletion had occurred, the corresponding position was omitted in the score calculation.

Selection of a representative set of natural HVR1 sequences

10 The NS1 HVR1 sequence from the HCV BK strain (residues 384-411) was used to search various databases (on 13 December 1995), both protein (SwissProt, PIR and Genpept, the latter representing assigned open reading frames from Genbank and EMBL) and nucleotide sequence (EMBL, Genbank and EST).

15 Duplicated and incomplete sequences were removed from the list of matching sequences to obtain a unique set of 234 natural HVR1 sequences.

Principle component analysis was used to select 40 sequences homogeneously distributed over the set. First, all pairwise distances between the 234 sequences were calculated using the first six eigenvalues calculated using Sequencespace (Casari et al., 1995). Sequences with the smallest distances to neighbouring sequences were eliminated in a stepwise procedure until only 40 sequences remained. Projections into two

dimensions along all possible pairs of Eigenvectors showed that the set of 40 sequences did not cluster and were homogenously distributed.

5 Accession numbers and sequences are:

- 1 Genbank:D12967 QTRTVGGQMGGHGVRLTSLFSAGSARN bp 46- bp 126
- 2 PIR:PC1193 STHVTGALQGRAAYGITSFLSHGPSQK aa 16- aa 42
- 3 Genbank:D00574 HTRVTGGVQGHVTSTLTSLFRPGASQK bp1240- bp1320
- 4 Genbank:L19383 ETHTSGGSVARAAFGLTSLFSPGAKQN bp 46- bp 126
- 5 Genbank:M62381 ETHVTGGSAGRTTAGLVGLLTPGAKQN bp1426- bp1506
- 6 Genbank:U24616 ATYTTGGSAAKTAHRLASFFTVGPKQD bp 22- bp 102
- 7 PIR:C48776 DTHVVGATERTAYS LTGLFTAGPKQN aa 13- aa 39
- 8 Genbank:U24607 GTTCQGGVYARGAGGIASLFSVGANQK bp 22- bp 102
- 9 PIR:D48766 RTLSFGGLPGHTTHGFASLSAPGAKQN aa 13- aa 39
- 10 Genbank:X60573 RTILMAGRQAEVTQSFPGLFSLAPSQK bp 46- bp 126
- 11 Genbank:D43650 NTHAMGGVVARSA YRITSFLSPGAAQN bp 1- bp 81
- 12 PIR:PQ0835 STRITGGSMARDVYRFTGFFARGPSQN aa 6- aa 32
- 20 13*Genbank:S73387 GTHTIGGSQAQQANRFVSMFSRGPSQK aa 190- aa 216
- 14 Genbank:D10934 NTYVTGGAAARGASGITSLSRGPQK bp1491- bp1571
- 15 Genbank:D31972 NTYASGGAVGHQTASFVRL LAPGPQQN bp1409- bp1489
- 16 Genbank:U14231 ETHTTGGEAARTTLG IASLFTSGANQK bp 103- bp 183
- 17 Genbank:U24602 ETHTTGGSAA RATFGIANFFTPGAKQN bp 22- bp 102
- 25 18 Genbank:L19380 ETYTS GGSAHTTSGFVSFFSPGAKQN bp 46- bp 126
- 19 Genbank:M74888 GTTRVGGA AARTTSSFASLLTHGPSQN bp1147- bp1227
- 20 Genbank:L12354 NTHTVGAAASRSTAGLTSLFSIGRSQK bp1468- bp1548
- 21 Genbank:X79672 NTRVTGGVQSRTTGTFVGLFTPGPSQR bp 1- bp 81

22 PIR:A48776 NTHVSGGRVGHHTTRSLTSFFTPGPQQK aa 13- aa 39
 23 Genbank:D12952 STRVSGGQQGRAAHSLTSLFTLGASQN bp 46- bp 126
 24 Genbank:D16566 STRITAQAEGRGASTLTSLFTSGASQK bp 8- bp 88
 25 Genbank:M84754 STIVSGGTVARTTHSLASLFTQGASQK bp1491- bp1571
 5 26 Genbank:D14853 ETRVTGGAAGHTAFGFASFLAPGAKQK bp1491- bp1571
 27 Genbank:S24080 NTYVTGGSAGRAVAGFAGLLQPGAKQN bp 46- bp 126
 28 Genbank:S35631 ETHSVGGSAHTTSRFTSLFSPGPQQN bp 580- bp 660

 29 Genbank:S62395 ETHVTGGSAASTTSTLTKLFMPGASQN bp 43- bp 123
 10 30 Genbank:S70291 QTRTVGGANARNTYGLTTLFTTGPKQN bp 1- bp 81
 31 Genbank:D88472 GTTTVGSASVSSTTYRFAGMFSQGAQQN bp1485- bp1565
 32 Genbank:D10687 NHTVGGTEGFATQRLTSLFALGPSQK bp1180- bp1260
 33 Genbank:D43651 NTHVTGGVARNAYRITTFLNPGPAQN bp 39- bp 119
 34 Genbank:D14305 HTYTTGGTASRHTQAFAGLFDIGPQQK bp1427- bp1507
 15 35 Genbank:X60590 KTHVTGMVAGKNAHTLSSIFTSGPSQN bp 46- bp 126
 36 Genbank:D30613 GTHVTGGKVAYTTQGFTSFFSRGPSQK bp1491- bp1571
 37 Genbank:X53131 EYTSGGNAGHTMTGIVRFFAPGPKQN bp 802- bp 882
 38 Genbank:U24619 STYSMGAAAHNARGLTSLFSSGASQR bp 22- bp 102
 39 Genbank:M62382 ETHVTGGSAGRSVLGIASFLTRGPKQN bp1426- bp1506
 20 40 Genbank:D88474 ETYIIGAATGRTTAGLTSLFSSGSQQN bp1488- bp1568

*Sequence 13 corresponds to the translated amino acid sequence
 (aa190-aa216) reported in the CDS feature of Genbank entry
 S73387.

25

Three additional sequences were also synthesized as MAPS: Two
 sequences are derived from the pedigreed HCV inoculum H77
 (Figure 2 of Farci et al., 1994):

41 (H77-1) ETHVTGGNAGRTTAGLVGLLTPGAKQN bp 1- bp 81
42 (H79) ETHVTGGSAGHTAAGIASFFAPGPKQN bp 1- bp 81

5 and one from the major isolate of a patient whose
immunoreaction has been characterized (Scarselli et al.,
1995):

43 Genbank:X79669 NTRVTGGVQSHTTRGFVGMFSLGPSQR bp 1- bp 81

10

Phage preparation and ELISA

Phage supernatants were prepared from XL-1 blue infected cells
as previously described (Folgori et al. 1994). ELISA were
15 performed according to Dente et al., (1994) using 25 μ l of
phage supernatant/well. Sera were diluted 1:100 if not
otherwise specified and revealed by addition of species-
specific anti-IgG (Fc-specific) alkaline phosphatase-
conjugated secondary antibodies (Sigma A-9544; dilution 1:5000
20 in ELISA blocking buffer). Results were recorded as
differences between O.D._{405 nm} and O.D._{620 nm} by an automated ELISA
reader (Labsystems Multiskan Bichromatic, Helsinki, Finland).

ELISA with phage pools were performed in the same way by using
25 equivalent amounts (10^{10} ampicillin transducing units) of
amplified phage after CsCl purification (see above).

100 μ l of MAPs representing natural HVR1 sequences were used to coat ELISA plates (Nunc Maxisorp, Roskilde, Denmark) at a final concentration of 10 μ g/ml in coating buffer (50mM NaHCO₃, pH 9.6). After blocking of free binding sites, 100 μ l/well of sera or affinity-purified antibodies were added. Mouse and rabbit sera were tested at final 1:100 dilution in blocking buffer; affinity purified antibodies were tested at final concentration of 150 ng/ml. Plates were incubated overnight at 4°C. After washing, 100 μ l/well of alkaline phosphatase conjugated secondary antibodies (goat anti-mouse IgG Sigma A-7434 diluted 1:2000; goat anti rabbit IgG Sigma A-8025 diluted 1:5000; goat anti human IgG Sigma A-9544 diluted 1:5000) were added and incubated one hour at room temperature. Plates were washed and alkaline phosphatase revealed as described above.

Affinity purification of antibodies from human sera

Multiple antigenic peptides reproducing the sequence of different mimotopes were used since they showed the same binding profile with HCV sera in ELISA as the phage, but proved to be more efficient in the affinity selection of the antibodies. Activated CH Sepharose 4B column (Pharmacia Biotech 17-0490-01) was coupled with the MAP of interest at the ratio of 1g of dried Sepharose/1mg of MAP in coupling buffer (0.1 M NaHCO₃, pH8/0.5M NaCl). Coupling was followed by

blocking of free amino-groups with 0.1M Tris-HCl pH8. Sample was loaded as a pool of eight HCV sera diluted 1:5 in coupling buffer. After adsorption at room temperature and extensive washing with PBS, bound antibodies were eluted with 0.1M glycine-HCl pH 2.7 supplemented with BSA at final concentration of 10 μ g/ml and immediately neutralised by 2M Tris-HCl pH9.4. The concentration of eluted antibodies was determined by ELISA using as standard human IgG (Sigma I-2511). Affinity-purified antibodies were checked for their reactivity in ELISA with the mimotope used for the purification (both in the form of MAP and phage) and, as control, with HCV-unrelated MAPs. The specificity of the purification was further confirmed by testing the eluted antibodies by ELISA on recombinant bacterially expressed HCV core protein (Prezzi et al., 1996) and by the second-generation HCV ELISA test (Ortho Diagnostic Systems, Bersee, Belgium). The total amounts of immunoglobulins recovered in each affinity purification from a standard amount of 1 ml of serum pool were comparable, ranging from 0.8 to 1.5 μ g. For ELISA on the test MAPs the concentration was adjusted in every case to 150 ng/ml.

Animal immunisations

25 Immunising phage were prepared from XL1-blue infected cells

and CsCl purified as previously described (Felici et al., 1991). Three to five weeks old female BALB/C mice (Charles River, Como, Italy) were immunised by intraperitoneal injection of 100 μ l of antigen solution at day 0, 21 and 42 and bled at day 52 (third bleed) and day 148 (fourth bleed). Phage were injected as 0.9% NaCl suspensions at a concentration of about 0.3 mg/ml (2.5×10^{13} phage particles/ml) without added adjuvant.

For peptide immunisations, MAPs were dissolved in PBS at a final total concentration of 400 μ g/ml and injected as a 1:2 dilution in either Complete Freund's Adjuvant (first injection) or Incomplete Freund's Adjuvant (booster injections). Four to seven weeks old female Balb/c mice (Charles River, Como, Italy) were immunised by i.p. injection of 100 μ l of antigen solution at weeks 0, 3 and 6 and bled at days 0 (pre-bleed) and 10 days after each additional injection. When more than one peptide were used for the immunization, equal amounts of each mimotope were mixed, and 100 μ l of a 400 μ g/ml solution was used.

EXAMPLE 6 - Immunogenic properties of peptides and E2 recombinant proteins. DNA immunisation in vivo.

Immunogenic properties of some of the selected HVR1 mimotopes

were explored either alone or as N-terminal fusion to the ectodomain of the E2 protein

The hcv E2 peptide is generally identified by the peptide
5 spanning from amino acid 384 to amino acid 809 of the HCV
polyprotein. The HVR1 region is generally identified as amino
acid 384 to 410. In the following examples Δ E2 identifies
peptides corresponding to aa411 to aa683 of the HCV
polyprotein.

Construction of recombinant plasmids

Three types of plasmids were produced and their structure is
reported in Figure 9:

15 (i) p Δ E2 - directing the synthesis of an E2 protein fragment
(HCV strain N, Nishihara et al.; Gene; 1993; 129 pp 207-214;
from aa411 to aa683 of the HCV polyprotein) carrying a
deletion of both the HVR1 and the C-terminal hydrophobic
region;

20 (ii) a second plasmid pF78 expressing one of the HVR1
mimotopes;

(iii) a set of 11 constructs (pMimoE2) in which DNA sequences
encoding for the eleven different HVR1 mimotopes were fused at
the 5' end of the Δ E2 coding sequence in the plasmid p Δ E2.

All recombinants were cloned in frame downstream of the tissue plasminogen activator (TPA) signal sequence to enforce secretion of the antigen.

5 Δ E2 gene (therefore coding for the peptides spanning from aa 411 to aa 683) was cloned using as PCR template an E2 N strain containing vector (Nishihara et al.; Gene; 1993; 129 pp 207-214). A PCR fragment was obtained using synthetic oligonucleotide primers

10 (oligo fwd = GCGAGATCTTAATTAACGATATCCAGCTTATAAAC;
oligo rev = TCCGGATCCTTAGTGGTGGTGGTGGTGGTGCGLAG). ^{GTAG}

By the use of these primers the resulting PCR product comprises, besides the Δ E2 gene, BglII, PacI and EcoRV
15 restriction sites at the 5' end, and a sequence coding for six histidine residues (His tag), and a TAA termination codon followed by BamHI restriction site at the 3' end. This PCR product is then digested with BglII and BamHI and ligated at the BglII site of V1JnsTPA vector (J.J. Donnelly et al. The
20 Journal of Infect. Diseases; 1996; 713; pp314-320) in frame with TPA leader sequence to obtain the plasmid V1JnsTPA- Δ E2 (designated p Δ E2 in Figure 9).

HVR1 mimotope sequences were subcloned at the 5' end of Δ E2

gene in pΔE2. HVR1 fragments were PCR-amplified directly from selected phage supernatant. The 5' primer contained PacI restriction site and was complementary to a 5' sequence (GGCGGCCGTTTAATTAAC) which is a constant part of HVR1 mimotope sequences; the 3' primers were complementary to the last 15 nucleotides and were different according to the mimotope sequence cloned. PCR-amplified fragments were PacI digested and ligated into pΔE2 plasmid. A total number of 11 pMimoE2 (Figure 9) plasmids were generated.

Furthermore a pF78 (Figure 9) plasmid was constructed by PCR amplification of F78 sequence (oligo fwd = GCGAGATCTTAATTAACCAGACCCATACCACC; oligo rev = TCCGGATCCTTAGTGGTGGTGGTGGTGGTTCTGTTTCGCGCC) and cloning at the BglIII site of V1JnsTPA vector.

Large-scale DNA preparations were performed using Qiagen 2500-Tip columns, following manufacturer's instructions (Qiagen, Hilden, Germany).

20 Characterisation of mimotope/E2 recombinant proteins

The ability of pF78, pΔE2 and pMimoE2 plasmids to drive the expression of recombinant proteins in a mammalian system was assessed by transient transfection of 293 cells. pΔE2 and

pMimoE2 transfected cells showed a strong and specific staining when probed with an anti-E2 monoclonal antibody (mAb-185) recognising an epitope located downstream of the HVR1. Also mF78 expression was demonstrated by immunocytochemistry of transfected 293 cells using a mice antiserum obtained by immunisation with a MAP reproducing the amino acid sequence of mimotope F78. These data were confirmed by ELISA on whole cell extracts from transfected cells. Significant amounts of all recombinant proteins were also secreted in the medium as measured by ELISA on cell culture supernatants from transfected cells.

Both intracellular and secreted proteins were heterogeneously glycosylated as suggested by their appearance as a cluster of slow migrating bands in SDS PAGE. The higher molecular weight displayed by the extracellular protein fraction is indicative of a different extent of glycosylation and confirms that the protein is actively secreted and not simply released by lysed cells. In both cases, endoglycosydase treatment leads to an increase of the migration rate to the one expected from the amino acid composition.

All recombinant mimotope/E2 fusion proteins as well as the Δ E2 mutant were efficiently recognised by two different conformation-sensitive monoclonal antibodies. Furthermore, no

cysteine-bridged multimeric aggregate was visible by Western blot on non reducing SDS PAGE of either the cellular or the secreted fraction from each clone. Similar results were obtained by transfecting mouse rhabdomyosarcoma cells thereby
5 providing indication that efficient expression will be achieved upon *in vivo* transfection of mouse muscle cells.

Plasmid DNA immunisation

10 Four weeks old female Balb/c mice (Charles River, Como, Italy) were used for immunisations. Fully anaesthetised mice received from 100 µg of plasmid DNA dissolved in 100 µl of saline buffer (PBS). Fifty microliters of DNA were injected bilaterally into quadriceps muscle via insulin syringe (B-D,
15 U-100 28G1/2 microfine needle). Mice were given three or four injections at 3-weeks intervals and were bled two weeks after each injection. Sera were analysed for antibody titre and cross-reactivity.

20 *Serology of α AE2 and α HVR1 antibodies*

ELISA 96 well plates (Immunoplate Maxisorp; Nunc, Roskilde, Denmark) were coated with 1 µg/well GNA (Sigma L8275) in 50 mM NaHCO₃ at pH 9.6 and incubated overnight at 4°C. Plates were

washed (PBS/0.1% Tween 20) and incubated 1 hr at 37°C with 250 µl/well of blocking buffer (2% BSA, 1X PBS, 0.1% Tween 20).

F78E2 or ΔE2 proteins were produced by transient transfection in 293 cells. 10X concentrated supernatant were used as

5 target antigen in ELISA. Saturating amount of each protein/well were incubated in blocking buffer 3 hrs at RT on GNA-coated plates. Serial dilutions of immune sera (from 1:100 to 1:72900) were pre-incubated for 2 hrs at RT with 1 µl/well of 10X supernatant from mock transfected 293 cells in
10 blocking buffer. Sera incubation was performed o/n at 4°C. After 1 hr at RT of IIAb incubation (α-mouse IgG Fc-specific AP conjugated, SIGMA 7434, diluted 1:2000 in blocking buffer), plates were developed for 30 minutes at 37°C.

15 Anti HVR1 mimotope antibodies were titrated (dilutions of sera from 1:100 to 1:72900) by ELISA assay using for each serum the homologous peptide sequence in the form of MAP.

In all cases sera titre was defined as the highest serum
20 dilution that resulted in an absorbance value of 0.3 O.D. (almost 6 times the background value).

Cross-reactivity assay

Sera were assayed for their cross-reactivity to different HVR1 natural variants using a set of 43 representative MAPS as described in Materials and Methods.

5 *Intramuscular injection of mimotope encoding constructs induces a strong humoral response*

Plasmids pΔE2 and pF78E2 were used to set up the optimal conditions for induction of humoral response. Induction of antibodies against epitopes located outside of the HVR1 was monitored by ELISA using the ΔE2 protein expressed by transiently transfected 293 cells. Balb/C and C57black mice were immunised to test the immunogenicity of the mimotope encoding constructs in different genetic backgrounds. Both the number of injections (from one to four) and the amount of injected DNA directly correlated with the magnitude of antibody response. The highest antibody titres against the ΔE2 protein were obtained after three injections at three weeks-intervals using fifty or one hundred micrograms of pΔE2 DNA per mouse. Further injections did not improve titres. A similar kinetic of induction of antibodies against the ΔE2 protein was observed following mice immunisation with plasmid pF78E2. Induction of anti-HVR1 antibodies in this latter group of animals was tested by ELISA on MAPF78. No

significant difference was observed between the two strains of mice under investigation as far as the optimal conditions of immunisation are concerned, but C57black mice showed on average better responses.

5

Antisera from mice immunised with the construct expressing only the F78 HVR1 mimotope (pF78) also induced a specific response, but the titres were much lower than those obtained by using the related pF78E2 construct. Several factors such as the level of expression, the folding of the recombinant products or the presence of stronger T helper epitopes might be responsible for the higher response observed with the fusion constructs as compared to the F78 mimotope alone.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252

(lower panel) using different individual plasmids or mixtures of plasmids. Crossreactivity is reported as number of peptides scored as positive of the 43 tested.

5 pB14E2 and pB24E2 plasmids did not induce a cross-reactive immune response, in spite of the presence of significant levels of antibodies specific for a peptide displaying the homologous mimotope sequence in the relative immune sera (Table III). All the other constructs gave rise to anti-sera
10 cross-reacting against some of the natural HVR1 sequences, with the anti-F78 sera being able to recognise up to 28% of the tested peptides (Table III).

The extent of cross-reactivity of the immune sera generally
15 reflected the immunogenicity of the individual plasmids as, in most cases, a higher titre corresponded to a higher level of cross-reactivity (Table III). Nevertheless, titre alone cannot always explain the differences in cross-reactivity, as shown with sera from mice immunised with plasmid pR6E2 which
20 induced lower titres than the pD6E2, pH1E2 and pM63E2 constructs, but reacted with a larger number of natural HVR1 peptides. Similarly, sera from mice immunised with the pF7E2, pM122E2 and pR9E2 showed a cross-reactivity two fold higher than that observed with the pG31E2 immune sera, despite
25 similar titres (Table III).

In C57Black mice injection of the pF78E2 chimaeric gene led to the development of a stronger response with a consequently higher cross-reactivity as compared to Balb/C mice (49% vs 28%).

5

Immunisation with mixtures of plasmids improves the cross-reactivity of the response

Three groups of Balb/C mice were immunised with mixtures of plasmids encoding for mimotope/E2 chimaeras, each mouse receiving a total amount of 100µg DNA/injection.

Mixture A contained the plasmids encoding for D6, F78, G31, H1, M122 and R6 fusions to E2. Mixture B also included the other three constructs that induced cross-reactive antibodies: pE19E2, pM63E2 and pR9E2, while Mixture C comprised all eleven plasmids. (Mixtures of peptides, and nucleic acid encoding peptides, according to each of Mixture A, Mixture B and Mixture C represent further aspects of the present invention.)

20

All three mixtures were immunogenic, and induced highly cross-reactive antisera (Table III). Antibodies from animals immunised with Mixture A did not show higher cross-reactivity as compared to those obtained by injecting individual plasmids included in the cocktails. However, it must be emphasised

25

that in the former case titres were about fifty fold lower, suggesting that Mixture A has the potential to induce a more widely cross-reacting response provided efficiency of the immunisation is increased. The results obtained with Mixture
5 B lent further support to this hypothesis. Mice receiving the second mixture of plasmids showed a net increase in cross-reactivity in that they developed anti-sera able to recognise about 50% of the tested natural HVR1 sequences. Also in this case the average titres were one order of magnitude lower than those displayed by the most cross-reacting sera from animals immunised with individual plasmids (Table III).

Intramuscular delivery of the most complex mixture including all plasmids encoding for the mimotope/E2 chimaeras did not further improve the breadth of reactivity of the resulting
15 immune sera. This result is consistent with the observed lack of cross-reactivity displayed by the animals immunised with the two additional constructs present in this cocktail (pB14E2 and pB24E2).

20 Similar data were obtained by immunising C57black mice.

REFERENCES

Alter, H.J. (1995) Blood 85, 1681-1695.

25 Bartoli, F., et al. (1996) BioTechniques 20 554-558.

- Bukh, J., 1995) Seminars in Liver Disease 15, 41-63.
- Casari, G., et al. (1995) Nature Structural Biology. 2, 171-178.
- Choo, Q.L., et al. (1989) Science 244, 359-362.
- 5 Choo, Q.L., et al. (1994) Proc. Natl. Acad. Sci. USA 91, 1294-1298.
- Cohen, J, (1993) Science 259: 1691-1692.
- Cormack, B.P. and Struhl, K. (1993). Science 262 244-248.
- Cortese, R., et al. (1994) Tibtech 12, 262-266.
- Cortese, R., et al. (1996) Current Opinions in Biotechnology 7, 616-621.
- Dente, L., et al. (1994) Gene 148, 7-13.
- Farci, P., et al. (1992) Science 258 135-140.
- Farci, P., et al. (1994) Proc. Natl. Acad. Sci. USA 91, 7792-7796.
- Farci, P., et al. (1996) Proc. Natl. Acad. Sci. USA 96, 15394-15399.
- Felici, F., et al. (1991) J. Mol. Biol. 222, 301-310.
- Folgori, A., et al. (1994) EMBO J. 13, 2236-2243.
- 20 Fried, M.W. and Hoofnagle, J.H. (1995) Semin. Liver Dis. 15, 82-91.
- Kato, N., et al. (1993) J. Virol. 67, 3923-3930.
- Kojima, M., et al. (1994) Virology 204, 665-672.
- Kurosaki, M., et al. (1994) Virology 205, 161-169.
- 25 Major, M.E., et al. (1995) J. Virol. 69, 5798-5805.

- Martell, M., et al. (1992) J. Virol. 66, 3225-3229.
- Martell, M., et al. (1994) J. Virol. 68, 3425-3436.
- Mast, E.E. and Alter, M.J. (1993) Semi. Virol. 4, 273-283.
- Mecchia, M., et al. (1996). J. Immunol., 157, 3727-3736.
- 5 Meola, A., et al. (1995). J. Immunol. 154, 3162-3172.
- Pessi, A., et al. (1990). J. Chem. Soc, Chemical
Communications, 1, 8-9.
- Prezzi, C., et al. (1996). J. Immunol. 156, 4504-4513.
- Scarselli, E., et al. (1995) J. Virol. 69, 4407-4412.
- 10 Shimizu, Y.K., et al. (1992) Proc. Natl. Acad. Sci. USA 89,
5477-5481.
- Shimizu, Y.K., et al. (1994) J. Virol. 65, 1494-1500.
- Shimizu, Y.K., et al. (1997). J. Virol. 71, 5769-5773.
- Silini, E., et al. (1995) Hepatology 21, 285-290.
- 15 Simmonds, P., et al. (1993). J. Gen. Vir. 74, 2391-2399.
- Tam, J.P. (1988) Proc. Natl. Acad. Sci. USA 85:5409-5413.
- van Doorn, L., et al. (1995) J. Virol. 69, 773-778.
- Weiner, A.J., et al. (1991). Virology 180, 842-848.
- Weiner, A.J., et al. (1992). Proc.Natl.Acad. Sci.USA 89 3468-
20 3472.
- Weiner, A., et al. (1995). Proc. Natl. Acad. Sci. USA 92,
2755-2759.
- Winter, G. and Milstein, C. (1991) Nature 349, 293-299.
- Yang, N.S., et al. (1990). Proc. Natl. Acad. Sci. USA 87: 9568-
25 9572.

TABLE I - Scheme of the selections.

First and second round of HVR1 library enrichment with sera from HCV infected patients are indicated at the top of the table. Names of the sera and the genotype of the
5 corresponding infecting virus (in brackets) are shown in the left column. In the right column are indicated the names of the resulting phage pools.

TABLE II - Amino acid frequencies observed in the set of "strong" and "weak" crossreactive mimotopes.

i indicates amino acid position (1 to 27); aa indicates amino acids in standard one letter code; $F_s(i,aa)$ is the frequency in position i of the amino acid aa in the "strong" mimotopes;
5 $F_w(i,aa)$ is the frequency in position i of the amino acid aa in the "weak" mimotopes.

Table I

Ist selection			IIInd selection		
serum/genotype		phage pool	serum/genotype		phage pool
$\sigma 4R$	(1b)	4R	$\sigma 2$	(1b)	B
$\sigma 3R$	(3a)	3R	$\sigma 1$	(1a)	D
$\sigma 3$	(2a)	3	$\sigma 2$	(1b)	E
$\sigma 2R$	(3a)	2R	$\sigma 3$	(2a)	R
$\sigma 1$	(1a)	1	$\sigma 4$	(2a)	F
			$\sigma 2$	(1b)	H
$\sigma 2P$	(2b)	2P	$\sigma 2$	(1b)	G
			$\sigma 1$	(1a)	L
			$\sigma 4$	(2a)	M
σN		N			

Table II

i	aa	Fs (i,aa)	Fw (i,aa)
1	Q	0.70	0.64
	T	0.30	0.36
2	T	1.00	1.00
3	H	0.52	0.28
	T	0.48	0.12
	R	0.00	0.60
4	T	0.70	0.52
	V	0.30	0.48
5	V	0.56	0.36
	T	0.44	0.64
6	G	1.00	1.00
7	G	1.00	1.00
8	Q	0.41	0.24
	S	0.30	0.56
	V	0.29	0.20
9	A	0.48	0.28
	Q	0.37	0.40
	V	0.15	0.32
10	S	0.44	0.64
	G	0.37	0.32
	A	0.19	0.04
11	H	0.82	0.40
	R	0.18	0.60
12	Q	0.52	0.44
	A	0.26	0.20
	T	0.22	0.36
13	A	0.37	0.28
	T	0.33	0.52
	V	0.30	0.20
14	S	0.48	0.32
	H	0.41	0.32
	R	0.11	0.36

i	aa	Fs (i,aa)	Fw (i,aa)
15	S	0.52	0.32
	G	0.41	0.24
	R	0.07	0.44
16	L	1.00	1.00
17	T	0.78	0.52
	V	0.22	0.48
18	S	0.48	0.24
	G	0.45	0.36
	R	0.07	0.40
19	L	1.00	1.00
20	F	1.00	1.00
21	S	1.00	0.20
	R	0.00	0.80
22	P	0.89	0.32
	L	0.07	0.28
	Q	0.04	0.32
	S	0.00	0.08
23	G	1.00	1.00
24	A	0.41	0.04
	S	0.37	0.20
	P	0.22	0.76
25	K	0.41	0.32
	S	0.41	0.36
	Q	0.18	0.32
26	Q	1.00	1.00
27	N	0.67	0.52
	K	0.33	0.48

Table III

plasmid	titre	n. positive peptides
pB14E2	270	0
pB24E2	189	0
pD6E2	4222	3
pE19E2	990	2
pF78E2	31812	12
pG31E2	31251	5
pH1E2	2977	1
pM63E2	3888	2
pM122E2	41360	10
pR6E2	1923	6
pR9E2	21092	11
mF78	110	2
MIX	684	11
MIX	1224	19
MIX	610	18

plasmid	titre	n. positive peptides
pF78E2	41547	21
MIX	20381	24